

C-Path's CPAD Database Drives Insights into Alzheimer's Disease

C-Path's Critical Path for Alzheimer's Disease (CPAD) Consortium is thrilled to share how Novo Nordisk A/S utilized the CPAD Alzheimer's disease database in their latest research presented at the Alzheimer's Disease and Parkinson's Disease Conference (#ADPD2025) in Vienna.

Novo Nordisk used C-Path's CPAD database, which holds data from 12,811 patients across 36 clinical trials of Alzheimer's disease (AD) and mild cognitive impairment, to study how BMI changes over time in early AD patients and examined how BMI affects trial dropout. All data in CPAD database has been remapped to a common data standard so that all the data can be analyzed across all studies. By leveraging our CPAD database, Novo Nordisk answered a question that would have been tough to solve with a single study or across separated datasets. This research highlights the importance of public-private partnerships and the power of a well-curated, aggregated, regulatory-grade clinical trial database in accelerating drug development and bringing effective treatments to patients faster.

Novo Nordisk's commitment to developing new therapies to help people with Alzheimer's disease and their families is clear. A big thank you to Novo Nordisk A/S for conducting this research and to all our CPAD member organizations and collaborators for sharing important patient-level clinical trial data that makes progress like this possible. Apply for access to the CPAD database [here](#). View the poster utilized during the presentation below or download it [here](#).

